Skip to main content
Subscribe
  • Login
  • My Account
  • Logout
  • Register For Free
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HLTH 2024
    • Sponsored Content: Vital Signs Blog
  • Opinion
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Healthcare Marketing Impact Awards
    • Innovators Awards
    • Diversity Leaders
    • Leading Women
    • Best in Business Awards
    • The 2030 Playbook Conference
    • Innovations in Patient Experience
    • Leading Women Conference & Awards Luncheon
    • Leadership Summit
    • Workforce Summit
    • Best Places to Work Awards Gala
    • Diversity Leaders Gala
    • - Looking Ahead to 2025
    • - Financial Growth
    • - Hospital of the Future
    • - Value Based Care
    • - Looking Ahead to 2026
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Skilled Nursing Facilities
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
    • Sponsored Content
MENU
Breadcrumb
  1. Home
  2. Providers
March 05, 2014 11:00 PM

Screening baby boomers for hepatitis C can become costly, physicians warn

Sabriya Rice
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Coverage for a one-time hepatitis C screening may soon be available for all Medicare beneficiaries born between 1945 and 1965.

    But new recommendations are already raising ethical and financial issues in the healthcare community over what to do with the millions who could be diagnosed. HCV treatments are limited, and those that are available are very expensive. Doctors must tell asymptomatic patients they tested positive, but face the ethical dilemma of deciding whether to treat them.

    Until recently, hepatitis C (HCV) screenings were recommended only for high-risk patients, such as users of injection drugs, people on long-term kidney dialysis, or individuals who had undergone blood transfusions before 1992. However, in August 2012 the Centers for Disease Control and Prevention issued recommendations saying all baby boomers should be screened.

    Nearly a year later, the U.S. Preventive Services Task Force extended its recommendations to do the same, upgrading screening for HCV to a grade B category, which says there is moderate benefit for patients.

    The CMS is the latest to follow suit. A representative from Medicare says this is the first time the program will include an HCV screening benefit. The agency's proposed recommendations for Medicare beneficiaries were posted Tuesday, and will be open for comment for 30 days. A final recommendation is anticipated by June.

    Approximately 3.2 million people in the U.S. have chronic hepatitis C, but most have not been diagnosed. HCV is “primarily a disease of the baby boomer population,” wrote the authors of a PLOS study, which found that between 2007 and 2009, the population of people age 65 and over diagnosed with chronic HCV had increased to 1.19 million, accounting for 75% of all patients with the disease, and 83% of patients with advanced disease.

    Because many people are asymptomatic, they look and feel fine, they remain undiagnosed. Over time, however, some—though not all—people with HCV can develop serious health problems, such as liver damage and liver cancer. By 2015, more than 300,000 may be diagnosed, the PLOS study projected.

    “The issue with screening is that it raises the question of what are you going to tell the patient,” said Dr. J. Mario Molina, president and CEO of Molina Healthcare, a group that helps several states manage pharmacy benefits for Medicaid enrollees. Though screening is indeed warranted, Molina noted, “there is currently no way of predicting which patient will develop liver disease and which will not.” Deciding whether to give a patient treatment has become an ethical predicament for many clinicians.

    “The desire to treat patients to prevent these consequences is great. But the treatments that we have had available are not very effective in clearing the infection, result in serious adverse effects including making patients feel sick during a prolonged treatment course, and are expensive,” Dr. Mitchell Katz, director of the Los Angeles County Department of Health Services, wrote in a JAMA editorial published in February. “For these reasons, neither I nor my patients have been very enthusiastic about treatment.”

    Drug companies have been racing to bring new medications to the market, with several announcements of potential treatments and research opportunities being made in the past few months.

    In December, the FDA approved Gilead's combination antiviral treatment regimen Sovaldi as a breakthrough therapy for treating chronic hepatitis C infections for four genotypes of the disease.

    This week, during the Conference on Retroviruses and Opportunistic Infections in Boston, AbbVie—formerly a part of Abbot Laboratories—announced early results of an investigational therapy tested in its pivotal phase III study, PEARL-III, which claimed their therapy could cure 99% of hepatitis C infections in patients with genotype 1 of the disease.

    Bristol-Myers Squibb, Roche and Merck are among several other pharmaceutical companies reported to be researching treatments. And this past July, the CDC announced a new collaboration with Quest Diagnostics on a hepatitis C research program in which they will share access to data about diagnostic, genotyping and viral load tests used by clinicians to manage treatment.

    In the meantime, treatment for the population that will need HCV medication in the future remains uncertain, causing insurers and physicians additional worry. The available drugs might be too costly, they say, to try to treat every potential patient. The issue was such a concern that several groups, including Molina Healthcare, sent letters to state Medicaid offices in January, requesting “emergency guidance” on how to handle “extraordinarily expensive” treatments.

    The letters note, for example, that it costs about $84,000 a patient to administer the full 12 course treatment of Gilead's Sovaldi. At that price, if all 300,000 Medicare patients projected to be diagnosed by 2015 were to seek treatment with the drug, the total expenditure could exceed $25 billion, and that's not including drug tests, doctor visits and other fees. The price tag for the drug, Molina said, is not sustainable.

    “Cost for much of the care is going to fall back on the taxpayers, and at a time when we're struggling just to get people insured, that is problematic,” he told Modern Healthcare. “You could probably insure 25 people per year, just with what it would cost to treat one person with that drug.”

    Follow Sabriya Rice on Twitter: @MHSrice

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    mh-20250513-Yellowstone-rural
    How 24 rural hospitals look to improve value-based care
    mh-20250509-dementia
    Federal dementia pilot has rocky rollout for some providers
    Most Popular
    1
    'Legendary' Hemsley takes over at UnitedHealth amid rough seas
    2
    Big retail tried to disrupt healthcare—who is making a dent?
    3
    These are the regulations the AHA wants RFK Jr. to scrap
    4
    Downside risk, upside payment highlight new CMS innovation agenda
    5
    Medicaid cuts bill clears key House committee
    Sponsored Content
    Modern Healthcare A.M. Newsletter: Sign up to receive a comprehensive weekday morning newsletter designed for busy healthcare executives who need the latest and most important healthcare news and analysis.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2025. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HLTH 2024
      • Sponsored Content: Vital Signs Blog
    • Opinion
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Healthcare Marketing Impact Awards
        • Innovators Awards
        • Diversity Leaders
        • Leading Women
        • Best in Business Awards
      • Conferences
        • The 2030 Playbook Conference
        • Innovations in Patient Experience
        • Leading Women Conference & Awards Luncheon
        • Leadership Summit
        • Workforce Summit
      • Galas
        • Best Places to Work Awards Gala
        • Diversity Leaders Gala
      • Virtual Briefings
        • - Looking Ahead to 2025
        • - Financial Growth
        • - Hospital of the Future
        • - Value Based Care
        • - Looking Ahead to 2026
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Skilled Nursing Facilities
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing
      • Sponsored Content